Author:
Zhang Xiuhong,Zhang Yan,Qiao Weizhen,Zhang Ji,Qi Zhigang
Funder
Wuxi medical and health guidance plan for scientific and technological development
Jiangsu Pharmaceutical Association-Aosaikang Hospital Pharmacy Fund
Jiangsu Pharmaceutical Association-Tianqing Hospital Pharmacy Fund
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference37 articles.
1. Y. Zhao, Z.X. Zhao, Y.J. Wang, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov, BioRxiv (2020) https://doi.org/10.1101/2020.01.26.919985 (access 3 Jun 2020).
2. W.J. Guan, Z.Y. Ni, Y. Hu, et al., Clinical characteristics of 2019 novel coronavirus infection in China, MedRxiv (2020) https://doi.org/10.1101/2020.02.06.20020974 (access 20 Feb 2020).
3. K.J. Xu, H.L. Cai, Y.H. Shen, et al., Management of corona virus disease-19 (COVID-19): the Zhejiang experience, Zhejiang Da Xue Xue Bao (Yi Xue Ban) (2020) http://kns.cnki.net/kcms/detail/33.1248.R.20200222.1417.002.html (in Chinese) (access 3 Mar 2020).
4. J.W. Zhang, X. Hu, P.F. Jin, Cytokine storm induced by SARS-CoV-2 and the drug therapy. Zhongguo Yao Xue Za Zhi (2020) http://kns.cnki.net/kcms/detail/11.2162.R.20200225.1052.002.html (in Chinese) (access 9 Feb 2020).
5. S.Y. Zhang, L. Li, A.Z. Shen, et al., Rational use of tocilizumab in the treatment of novel coronavirus pneumonia, Clin. Drug Investig. (2020) https://doi.org/10.1007/s40261-020-00917-3 (access 29 Apr 2020).
Cited by
127 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献